Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the Phase III BREAKWATER trial led by researchers at The University of Texas MD Anderson Cancer Center.
This cross-sectional study reports on the study design characteristics of clinical trials for novel psychiatric drugs approved by the US Food and Drug Administration.
Can you separate fact from fiction when it comes to emerging treatments for IgA nephropathy? Test your knowledge with this quiz.
KFF Health News Southern correspondent Sam Whitehead made the rounds on local radio recently to discuss topical stories. Here’s a collection of his appearances.
Only a tiny percentage of people addicted to alcohol or drugs take medication for it. Why not? It’s complicated, but the approved medications are not…
ITEXPO and the #TechSuperShow started in 1999 with 62 exhibitors and 1,500 attendees; over the past 25 years growth has exploded.
This cohort study examines expected vs observed rates of firearm-related injury hospitalizations in the US during the COVID-19 pandemic.
This qualitative study presents a framework to assist primary care clinicians in navigating surgical care for older patients.
Why have philosophers historically failed to think seriously about privacy? How do invasions of privacy really impact a person? What do we give up when…
Celebrate innovation in enterprise technology with the We Love Tech Awards! Nominate visionary leaders, groundbreaking products, and transformative organizations. Submit by March 28, 2025, and…
As wildfires rage across Los Angeles (CA, USA), the region’s health systems are confronting an extraordinary test, exposing vulnerabilities that demand urgent attention. The crisis…
